1. Myers PR, Webel R, Thondapu V et al. Restenosis is associated with decreased coronary artery nitric oxide synthase. Int J Cardiol 1996; 55: 183–91.
2. Wu TC, Chen YH, Chen JW et al. Impaired forearm reactive hyperemia is related to late restenosis after coronary stenting. Am J Cardiol 2000; 85: 1071–6.
3. Ikeda U, Yamamoto K, Maeda Y et al. Endothelin-1 inhibits nitric oxide synthesis in vascular smooth muscle cells. Hypertension 1997; 29: 65–9.
4. Piatti PM, Fragasso G, Monti LD et al. Acute intravenous L-arginine infusion decreases endothelin-1 levels and improves endothelial function in patients with angina pectoris and normal coronary arteriograms: correlation with asymmetric dimetylarginine levels. Circulation 2003; 107: 429–36.
5. Piatti PM, Colombo A et al. Association of Insulin Resistance, Hyperleptinemia, and Impaired Nitric Oxide Release With In-Stent Restenosis in Patients Undergoing Coronary Stenting. Circulation 2003; 108: 2074–81.
6. Cooke JP, Oka RK. Does leptin cause vascular disease? Circulation 2002; 106: 1904–5.
7. Recchia FA, Vogel TR, Hintze TH. NO metabolites accumulate in erythrocyte in proportion to carbon dioxide and bicarbonate concentration. Am J Physiol Heart Circ Physiol 2000; 279: H852–6.
8. Piatti P, Fragasso G, Monti LD et al. Endothelial and metabolic characteristics of patients with angina and angiographically normal coronary arteries: comparison with subjects with insulin resistance syndrome and normal controls. J Am Coll Cardiol 1999; 34: 1452–60.
9. Yamagishi SI, Edelstein D, Du XL et al. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 2001; 276: 25096–100.
10. Wallace AM, Mc Mahon AD, Packard CJ et al. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 2001; 104: 3052–6.
11. Doehner W, Rauchhaus M, Godsland IF et al. Insulin resistance in moderate chronic heart failure is related to hyperleptinemia, but not to norepinephrine or TNF-alpha. Int J Cardiol 2002; 83: 73–81.
12. Soderberg S, Stegmayr B, Ahlbeck-Glaber C et al. High leptin levels are associated with stroke. Cerebrovasc Dis 2003; 15: 63–9.
13. Versaci F, Gaspardone A, Tomai F et al. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS Study). J Am Coll Cardiol 2002; 40: 1935–42.
14. Schillinger M, Exner M, Mlekusch W et al. Acute-phase response after stent implantation in the carotid artery: association with 6-month in-stent restenosis. Radiology 2003; 227: 516–21.
15. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–9.
16. Bergman RN. Lilly lecture 1989. Toward physiological understanding of glucose tolerance: minimal-model approach. Diabetes 1989; 38: 1512–27.
17. Takagi T, Yoshida K, Akasaka T et al. Hyperinsulinemia during oral glucose tolerance test is associated with increased neointimal tissue proliferation after coronary stent implantation in non diabetic patients: a serial intravascular ultrasound study. J Am Coll Cardiol 2000; 36: 731–8.
18. Iozzo P, Chareonthaitawee P, Dutka D et al. Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes 2002; 51: 3020–4.
19. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003; 46: 3–19.
20. Bergman RN, Finegood DT, Kanh SE. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 2002; 32 (suppl. 3): 35–45.
21. The Decode Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617–21.
22. Norhammar A, Tenerz A, Nilsson G et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002; 359: 2140–4.
23. Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularisation. N Engl J Med 2002; 346: 1773–80.
24. Kaiser C, Brunner-La Rocca H, Buser P et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trail (BASKET). Lancet 2005; 366: 921–9.

Н.М.Данилов, Т.Т.Горгадзе, А.П.Савченко, И.Е.Чазова

Отдел системных гипертензий ФГУ РКНПК Росздрава, Институт кардиологии им. А.Л.Мясникова, Москва